Foghorn Therapeutics Inc. Stock Price, News & Analysis

Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced that CEO Adrian Gottschalk will participate in the virtual Evercore ISI HealthCONx Conference on November 30, 2022, at 2:40 p.m. ET. The company focuses on gene expression treatments for serious diseases, particularly in oncology, using its Gene Traffic Control platform. The event will include a fireside chat, and a webcast will be available on the company's website for 90 days. Foghorn is developing innovative medicines that target chromatin regulatory systems.

Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced preclinical data for FHD-609, a first-in-class BRD9 degrader, at the 2022 CTOS Annual Meeting, set for November 16–19, 2022, in Vancouver, Canada.

The presentation on November 17, 2022, will detail FHD-609's potential in treating synovial sarcoma, a rare, aggressive cancer. With approximately 800 new cases annually in the U.S., current treatments are limited. FHD-609's preclinical studies show promise in inhibiting tumor growth. For further data, access the poster post-presentation via the company's website.

Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced new preclinical data for its FHD-286 program during the SITC 37th Annual Meeting held from November 8-12, 2022. The data highlights the efficacy of FHD-286, a BRG1/BRM inhibitor, in combination with an anti-PD-1 antibody, showcasing improved survival benefits in preclinical models. FHD-286 is in Phase 1 trials targeting metastatic uveal melanoma and acute myelogenous leukemia, although the AML and myelodysplastic syndrome trial is currently on clinical hold. The poster presentation is scheduled for November 11, 2022.

Foghorn Therapeutics (FHTX) provided an update on its clinical trials and financial position. The Phase 1 study of FHD-286 in metastatic uveal melanoma continues to progress, with initial data anticipated in 2023. The FHD-609 program shows promise in synovial sarcoma. The company's strong balance sheet, with $373.5 million in cash as of Sept. 30, 2022, extends its financial runway into 2025. Collaboration revenues for Q3 2022 reached $6.6 million. However, a full clinical hold by the FDA on FHD-286 for AML/MDS due to safety concerns remains a notable challenge.

Foghorn Therapeutics (Nasdaq: FHTX) has elected Dr. Thomas Lynch Jr. to its Board of Directors. Dr. Lynch, president of Fred Hutchinson Cancer Center and former Chief Scientific Officer at Bristol-Myers Squibb, brings extensive scientific and clinical expertise to the role. His appointment comes as Foghorn progresses clinical trials for drug candidates FHD-609 and FHD-286. CEO Adrian Gottschalk emphasized the value of Dr. Lynch's experience in guiding the company's growth. This leadership addition could enhance Foghorn’s capabilities in drug development and strengthen its mission to address serious diseases.

Foghorn Therapeutics (FHTX) presented promising initial Phase 1 data highlighting the degradation of BRD9 in metastatic tumor biopsies of synovial sarcoma using FHD-609. This investigational drug demonstrates strong selectivity and efficacy, potentially leading to significant tumor growth inhibition. The company also introduced a new protein degrader program targeting EP300 mutations, which could benefit over 100,000 patients annually. The data reinforces Foghorn's status as a leader in protein degradation therapies, with further detailed results expected in 2023.

Foghorn Therapeutics (Nasdaq: FHTX) announced its participation in the 5th Annual Targeted Protein Degradation Summit from October 25-28, 2022, in Danvers, Massachusetts. The company will present initial pharmacodynamic data from its Phase 1 study of FHD-609, a selective degrader of BRD9 for treating synovial sarcoma and SMARCB1-loss tumors. Notable sessions include a keynote by Danette L. Daniels, Ph.D., on October 26, and a workshop on preclinical study design on October 25. Foghorn is advancing its protein degradation platform amid ongoing clinical studies.

Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotech firm, will participate in the Bank of America 2022 Precision Oncology Conference on October 3, 2022, at 12:20 p.m. ET. The company's innovative Gene Traffic Control platform aims to address gene expression issues in serious diseases, with a primary focus on oncology. A webcast of the event will be available on their website for 90 days post-event. Foghorn is developing several oncology product candidates, with two currently in clinical trials.

Foghorn Therapeutics (Nasdaq: FHTX) has announced management's participation in key investor conferences this September. The biotechnology company focuses on developing innovative treatments by correcting abnormal gene expression, particularly in oncology. The upcoming conferences include the Morgan Stanley 20th Annual Global Healthcare Conference on September 12 and the H.C. Wainwright 24th Annual Global Investment Conference on September 13. Webcasts of these events will be available on their website for 90 days post-conference.